The majority of patients can be managed with non-invasive diagnostic tests
At present, two main options are available for the management of patients with von Willebrand disease: DDAVP and blood products containing VWF. In addition, tranexamic acid, an anti-fibrinolytic agent, can be used alone in the management of epistaxis and menorrhagia and it is used in combination with DDAVP-or VWF-containing concentrates to cover dental extractions and surgery.
DDAVP causes VWF to be released from endothelial stores. The mechanism for the rise in factor VIII was thought to be due to its consequent stabilisation in plasma. However, the use of DDAVP in type 2N disease indicates that it must also release factor VIII from a storage pool. It is often effective in type 1 disease where increasing levels 2-5 fold is sufficient for haemostasis. It is of no use in type 3 disease. In types 2A and 2M, increasing the levels of the abnormal VWF has a variable effect. DDAVP therapy is controversial in type 2B disease as the release of the abnormal VWF may induce platelet agglutination and thrombocytopenia. If DDAVP cannot be used or is ineffective, a plasma-derived concentrate must be used. The clinical assessment of symptoms and signs can do no more than raise a suspicion of the diagnosis. Objective diagnostic methods must be used to confirm or exclude DVT and/or PE. There is increasing interest in the negative predictive value of D-dimer tests, which can be used to limit the use of radiology. D-dimer is a fibrin degradation product indicative of in vivo thrombin activity. Rapid enzyme-linked immunosorbent assays (ELISA) and automated latex agglutination methods are both quick and sensitive. D-dimer tests should be used in conjunction with pre-test clinical probability scoring because the negative predictive value depends not only on the sensitivity and specificity of the test but also on the prevalence of VTE. Thus, a patient with a negative D-dimer result but a moderate pre-test clinical probability score (see Table 1 ) still has about a one in 50 risk of VTE, whereas a patient with a high pretest clinical probability score has a one in five risk of VTE even with a negative Ddimer result 3 .
Further reading

Initial therapy: anticoagulation
Anticoagulation is standard therapy for patients with VTE who are clinically stable (other treatment options are shown in Table 2 ), except patients in whom anticoagulation is contraindicated. Insertion of a vena caval filter may be more appropriate. Some patients are haemodynamically unstable and may benefit from initial thrombolytic therapy before starting anticoagulation.
Unfractionated heparin
Unfractionated heparin (UFH) should be given either as a continuous intravenous infusion or by twice daily subcutaneous injection at a dose sufficient to prolong the activated partial thromboplastin time ratio to 1.5-2.5 times normal (level Ia). (The levels of evidence are according to the US Agency for Health Care Policy and Research, summarised in the British Committee for Standards in Haematology (BCSH) guidelines on oral anticoagulation 4 ). Weight-based dosing schedules have been developed for both intravenous and subcutaneous therapy. Treatment with heparin should continue for at least five days (level Ib) and until the international normalised ratio (INR) is therapeutic. For patients with large thromboses heparin may be administered for a longer period (up to 10 days).
UFH should be reserved for the small number of patients who require emergency invasive procedures when it is useful to be able to 'turn on and off ' the anticoagulant effect at will. This is not possible with once daily administration of low molecular weight heparins (LMWHs). Furthermore, the anticoagulant effect of UFH can be completely reversed with protamine sulphate whereas this is not possible with LMWH.
Low molecular weight heparin
Treatment with LMWH results in a lower risk of thrombotic and haemorrhagic complications and a lower mortality than treatment with UFH 5 (level Ia). Most LMWH studies to date have selected patients with DVT. More recently, randomised studies of patients with PE have extended the treatment indications to include patients with submassive PE, thus making this class of heparin the treatment of choice for most patients with VTE.
Two multicentre clinical trials have confirmed the feasibility, efficacy and safety of outpatient treatment of DVT 6, 7 (level Ib). The possibility of extending home therapy to patients with symptomatic PE is supported by a recent study 8 and also the ability to identify low risk patients suitable for home treatment 9 . Factors associated with death, recurrence or haemorrhage are cancer, heart failure, previous DVT, hypoxia, hypotension and the presence of DVT on ultrasound 9 . As outpatient therapy is now appropriate for most patients with DVT, it is likely to be extended to low risk patients with PE.
Warfarin
Warfarin can be commenced on day 1 in conjunction with heparin in most patients with VTE. A standard protocol for the commencement of oral anticoagulant treatment is recommended and treatment should be monitored with the INR 4 . A target INR of 2.5 gives the lowest VTE recurrence and bleeding rates (level Ib) 4 .
Duration of anticoagulation
Opinion varies as to the optimal duration of therapy. After a first episode of VTE the recommendations range from three months when there is a reversible transient risk factor, to two years in young patients with idiopathic VTE. The BCSH considers the distinction between proximal and calf vein thrombus (CVT) as an important factor in decision analysis. It makes the following recommendations for duration of treatment (level Ib) 4 :
patients with a first episode of proximal DVT or PE: six months idiopathic CVT: three months postoperative calf vein clots: six weeks.
Calf vein thrombi: to treat or not to treat?
When confined to the calf, DVT is associated with a low risk of clinically important PE. Untreated, or inadequately treated, CVT may extend proximally in 5-30% of patients 10 . Symptomatic CVT that extend usually do so in the first five days after symptoms develop, with extension or recurrence rare after the first week 11 . Treatment with heparin alone for five days does not eliminate the risk of extension but simply delays this complication until after anticoagulation is stopped. Treatment of CVT with anticoagulation for six weeks to three months virtually eliminates the risk of proximal extension and PE. As an alternative to anticoagulant treatment, small CVT can be monitored with serial non-invasive tests (eg compression ultrasound examination) and treated as for a proximal thrombus if extension occurs.
Influence of thrombophilia testing on management decisions
The ability to 'explain' thrombosis has led to the increasing use of thrombophilia testing in the assessment of patients with VTE 12 . However, studies confirming a beneficial outcome from testing are lacking. Thrombophilia testing does not predict likelihood of heparin resistance, heparin failure or warfarin-induced skin necrosis 13 . At present, there is no evidence that recurrence on treatment with warfarin with a target INR of 2.5 is greater in patients with thrombophilia than in those without 13 . There is no conclusive evidence that, in general, patients with heritable thrombophilia are more likely to suffer an earlier recurrence once treatment is stopped 14 . Possible exceptions are patients homozygous for the factor V Leiden mutation and patients with very high factor VIII levels. Further management studies are required to determine whether the benefit:risk ratio of extended anticoagulant therapy is favourable in these small subgroups of patients.
In contrast to heritable thrombophilia, prospective data indicate that detection of acquired lupus anticoagulant or anticardiolipin in a patient with thrombosis indicates a high risk of future thrombosis 15 . However, even in this situation a conventional six-month period of anticoagulation after a first event has recently been recommended by the BCSH as only level IV evidence is available 16 .
Prevention of chronic venous hypertension
The incidence of postthrombotic syndrome (PTS) due to chronic venous insufficiency has been decreasing in recent years, suggesting that more efficient treatment of VTE and the prevention of recurrent DVT can have a positive impact on this complication. A randomised study of calf length, madeto-measure, elastic compression stockings worn for two years compared with no stockings in patients with a first episode of proximal DVT demonstrated a significant reduction in PTS 17 .
CME Haematology -II
Sickle cell disease (SCD) affects 12,000 individuals in the UK 1 and imposes a severe health burden on many. Frequent crises mean interrupted education and cause employment difficulties. In the third and fourth decades, chronic endorgan damage may predominate. Median life expectancy is reduced to the mid-40s even with optimal care 2 .
Although some complications require hospital admission, a wider care model is appropriate involving health and social care agencies across acute and community boundaries. Full involvement of patients and carers in developing services is critical.
The term 'SCD' includes: homozygosity for the b S gene, resulting in sickle cell anaemia (HbSS), usually the most severe form of SCD, and compound heterozygosity with other abnormal b genes, resulting in HbSC, Sb thalassaemia, SD Punjab , SE and SO Arab , and some rarer phenotypes such as SLepore.
Abnormal b globin chains cause deranged conformation of haemoglobin molecules producing distorted erythrocytes, some sickle-shaped. Erythrocyte survival is shortened, rheology deranged with disturbed interaction between erythrocytes and vascular endothelium, and dysregulation of vascular reactivity. Small and large vessel occlusions result. Lack of significant morbidity for HbAS heterozygotes (sickle cell trait) and their relative protection against death from malaria in childhood are well documented. Current theories of pathogenesis are reviewed by Steinberg 3 (also at www.asheducationbook.org/ current.shtml).
Screening
Up to 40% of African, Afro-Caribbean, Asian, South-East Asian and Mediterranean populations are carriers. Only in people of strictly Northern European origin are carriers rare.
